Evidence map›Paper›PMID 30104905›Full record

ArticleInternational medical case reports journal2018

Remission of nephrotic syndrome after surgical intervention for bronchogenic carcinoma: the 10-year follow-up of a patient with membranous nephropathy.

Izumi Nagayama, Tetsu Akimoto, Yuko Ono, Yoshihiko Ueda, Daisuke Nagata

Abstract readCase Reports
In one paragraph

Article in International medical case reports journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Izumi NagayamaDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan, tetsu-a@jichi.ac.jp.
Tetsu AkimotoDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan, tetsu-a@jichi.ac.jp.
Yuko OnoDepartment of Pathology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan.
Yoshihiko UedaDepartment of Pathology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan.
Daisuke NagataDivision of Nephrology, Department of Internal Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan, tetsu-a@jichi.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nephrotic syndrome (NS) is a pivotal manifestation of glomerular injury associated with various types of neoplasms. It may either precede or act as the presenting feature of the disease, whereas membranous nephropathy (MN) is a major phenotype of paraneoplastic glomerulopathies. However, there is a lack of information regarding the remission from paraneoplastic NS due to MN in patients who achieve favorable long-term survival after the successful removal of malignant tissue. We, herein, describe a case of biopsy-proven MN in a 65-year-old male patient with bronchogenic carcinoma, which was found during the systemic workup for concurrent NS. He was successfully treated with thoracoscopic left lower lobectomy and achieved a complete remission from NS at approximately 10 months after radical surgery. In 10 years of follow-up, there has been no recurrence of the pulmonary cancer and the patient is doing well with no relapse of NS, despite having never received treatment with any type of immunomodulating agent. Several concerns, including diagnostic management and therapeutic strategies for paraneoplastic NS, are discussed.

Indexed as

membranous nephropathynephrotic syndromeparaneoplastic kidney diseasepulmonary cancerremission

Identifiers

PMID30104905
PMCPMC6071629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.